Pharma and Biotech News | The Pharmaletter
WEB2 days ago · USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 …
Schizophrenia win for BMS’ Cobenfy, but challenges lie ahead, says ...
WEB11 hours ago · US pharma major Bristol Myers Squibb’s (NYSE: BMY) recent approval from the US Food and Drug Administration (FDA) for Cobenfy (xanomeline and trospium chloride) for the treatment of adults with schizophrenia is a win for the company. However, as the drugs most widely used to treat schizophrenia are inexpensive, genericized atypical antipsychotics, the schizophrenia market is competitive and ...
Boehringer enters novel precision cancer collab with Circle Pharma
WEB10 hours ago · German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers.
Bayer and MOMA strike new oncology partnership
WEB10 hours ago · Bayer (BAYN: DE) has partnered with MOMA Therapeutics to develop a small molecule oncology program using MOMA’s KNOMATIC platform. Bayer will handle development, preclinical work, and commercialization. MOMA receives upfront and milestone payments, plus royalties. The deal follows MOMA's January collaboration with …
Pharma, Biotech and Generics Industry News | The Pharmaletter
WEBSep 24, 2024 · Pharmaceutical. 30 September 2024 India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. Generics. 30 September 2024 The number of clinical trials of new drugs in Russia is steadily declining, which could be …
Pharmaceutical Industry News | The Pharmaletter
WEBSep 24, 2024 · Mergers and Acquisitions. The Pharma Letter M&A roundup - September 2024. Pharma dealmakers appear to have largely remained on their summer holidays in a month when none of the industry's biggest players announced acquisitions.2 October 2024. M&A activity – new inflammatory disease targets …
FDA drug regulation and approval news | The Pharmaletter
WEBOct 2, 2024 · FDA clears Dupixent, first-ever biologic for COPD. The US Food and Drug Administration (FDA) on Friday approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. 28 September 2024. Biotechnology.
The week in pharma: action, reaction and insight – week to …
WEB3 days ago · Important regulatory news last week included French pharma major Sanofi gaining approval from the US Food and Drug Administration (FDA) and the Chinese medicines authority for its blockbuster drug Dupixent as the first biologic for chronic obstructive pulmonary disease (COPD). Spanish epigenetics firm Oryzon Genomics announced that, with FDA feedback, it is preparing for a Phase III trial of ...
The Pharma Letter M&A roundup - August 2024 | The Pharmaletter
WEBOct 2, 2024 · August was a quiet month for pharma dealmaking, with few major acquisitions from industry giants. Notably, Organon agreed to purchase Dermavant Sciences from Roivant for $1.2 billion, and Australian biotech Telix Pharmaceuticals acquired USA-based RLS Radiopharmacies, highlighting continued growth in the radiopharma sector. The following table and graphs provide a comparative look at monthly ...
Pharma and Biotech News in Brief | The Pharmaletter
WEBSep 6, 2024 · UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024. Biotechnology.